Collaborative Drug Discovery Inks Deal with Eli Lilly to Accelerate Biotech Innovation

Lilly created Lilly TuneLab to accelerate biotech innovation by enabling participating companies to access models trained on Lilly’s proprietary research data. Through this agreement, biotech companies that use CDD Vault will be able to utilize select Lilly predictive models within their natural scientific workflows, according to Barry A. Bunin, Collaborative Drug Discovery (CDD) president and CEO.

“By integrating TuneLab directly into CDD Vault, we are advancing CDD’s core vision to enable collaboration across drug discovery teams and organizations. We believe that solving the most complex challenges in drug discovery will depend on innovative collaboration models that provide broad access to research data and empower chemists and biologists to make informed, data-driven decisions,” said Bunin. “TuneLab’s ADMET models will fit in our secure CDD Vault software environment in natural workflows for experimental and computational scientists and with our growing CDD Vault ecosystem of biopharmaceutical companies.”

This agreement paves the way for the planned integration of Lilly TuneLab in both the core and AI modules within CDD Vault for biotech companies that opt into the program. A company spokesperson explained that the agreement builds on CDD’s founding vision from 2004 to demonstrate the economics of efficiency of web-based collaboration.

“TuneLab’s models are synergistic with our innovations such as Zero Click Models, Generative Bioisosteres, as well as Ultrafast Deep Learning similarity to SureChEMBL for novelty and Enamine libraries for convenient SAR-by-catalog,”  noted CDD research informatics senior scientist Peter Gedeck, PhD.